- Price
- $18.39
- Day
- -1.87%
- Mkt Cap
- $35.31B
- 52W Range
- $14.02 – $20.13
- Volume
- 16.22M
- Beta
- 0.43
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Kenvue's Brand Strength and Innovation Strategy Support Growth
KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.